Hemorrhagic Vasculopathy after Treatment of Central Nervous
System Neoplasia in Childhood: Diagnosis and Follow-up
Tina Young Poussaint, Joao Siffert, Patrick D. Barnes, Scott L. Pomeroy, Liliana C. Goumnerova, Douglas C. Anthony,
Stephen E. Sallan, and Nancy J. Tarbell
PURPOSE: To review the clinical data, imaging findings, and intermediate outcomes of a series of
children with hemorrhagic vasculopathy after treatment for intracranial neoplasia. METHODS: We
retrospectively analyzed the medical records and imaging examinations of 20 pediatric patients
(ages 1 to 15 years) with intracranial neoplasia in whom delayed intracranial hemorrhage developed after cranial irradiation or radiation combined with systemic or intrathecal chemotherapy.
Patients with intracranial hemorrhage from other identifiable causes were excluded. Histopathologic analysis was available in four patients. RESULTS: Twenty patients with delayed intracranial
hemorrhage received cranial irradiation alone (n59) or combined radiation and chemotherapy
(n511) for primary brain tumors (n513), leukemia (n56), or lymphoma (n51). Imaging findings
were consistent with hemorrhages of varying ages. The hemorrhages were not associated with
tumor recurrence nor second tumors. Except for location of the hemorrhage, no significant
relationship was established between outcome and original diagnosis, radiation dose (range, 1800
to 6000 centigray), chemotherapeutic agent or dosage, age at treatment, or interval between
therapy and hemorrhage (mean, 8.1 years). Only brain stem hemorrhage was associated with a
poor outcome. CONCLUSION: In children with central nervous system neoplasia who have
undergone cranial irradiation, or radiation combined with chemotherapy, delayed intracranial
hemorrhage may develop.
Index terms: Brain, effects of irradiation on; Brain neoplasms; Cerebral hemorrhage; Children,
neoplasms
AJNR Am J Neuroradiol 16:693–699, April 1995
Intracranial hemorrhage is a rare, late delayed effect of treatment for central nervous
system tumors that has been described in a
small number of children (1, 2) and adults (3,
4). Such an effect must be distinguished from
recurrent tumor and from radiation-induced
second tumors. The purpose of this study was to
review the clinical aspects, imaging findings,
and intermediate outcome in a larger series of
children with delayed intracranial hemorrhage
after treatment for intracranial neoplasia, and to
evaluate clinical and therapeutic factors that
may predict it.
Methods
We retrospectively analyzed the medical records and
imaging examinations of 20 pediatric patients in whom
intracranial hemorrhage developed after cranial irradiation, or radiation plus chemotherapy, as identified by imaging during the period from November 1987 through
October 1993, and who had no evidence of recurrent tumor nor other potential cause of central nervous system
hemorrhage. The imaging studies included computed tomography (CT) in 1 patient, magnetic resonance (MR) in
10 patients, and both CT and MR in 9 patients. Axial
10-mm CT sections were obtained without contrast enhancement through the entire brain, usually with 5-mm
axial sections through the posterior fossa. Contrastenhanced CT was performed in 2 patients similarly after
the intravenous injection of ioversol at a dosage of 2.22
Received June 29, 1994; accepted after revision October 10, 1994.
From the Departments of Radiology (T.Y.P., P.D.B.), Neurology (J.S.,
S.L.P.), Neurosurgery (L.C.G.), Neuropathology (D.C.A.), Medicine
(S.E.S.), and Radiation Oncology (N.J.T.), Children’s Hospital, Joint Center for Radiation Therapy, Department of Pediatric Oncology, Dana Farber
Cancer Institute, and Harvard Medical School, Boston, Mass.
Address reprint requests to Tina Young Poussaint, MD, Department of
Radiology, Section of Neuroradiology, Children’s Hospital, 300 Longwood
Ave, Boston, MA 02115.
AJNR 16:693–699, Apr 1995 0195-6108/95/1604 –0693
q American Society of Neuroradiology
693
694
POUSSAINT
AJNR: 16, April 1995
ml/kg (1 ml/lb). MR exams were performed using a 1.5-T
General Electric (Boston, Mass) Signa system with imaging parameters of 5-mm section thickness, 2.5-mm gaps,
256 3 192 matrix, and 24-cm field of view for sagittal
T1-weighted conventional spin-echo images (600/20/2
[repetition time/echo time/excitations]), and axial proton
density (2000/17/1) and T2-weighted (3200/85/2) fast
spin-echo images. Additional coronal T1, proton density,
or T2 sequences were often performed. Contrast material
was administered in 10 patients: gadopentetate dimeglumine (4) or gadoteridol (6) at a dosage of 0.1 mmol/kg
intravenously. Follow-up imaging exams were available in
9 patients. The CT and MR parameters studied included
size and number of lesions, location, density, intensity, and
enhancement. Because the total sample size was 20,
Fisher’s Exact Test (5) was used for statistical analysis
with regard to predictors of outcome.
Results
Of the 20 patients identified (Table), 13 had
primary brain tumors, 6 had leukemia, and 1
had lymphoma. There were 12 girls and 8 boys.
All 20 patients underwent cranial irradiation,
Clinical and follow-up data: 20 children with irradiated intracranial neoplasms and delayed hemorrhagic vasculopathy
Age at
Patient Hemorrhage,
y/Sex
Initial
Diagnosis
Radiation
Dose,
centigray
Years
Clinical
Presentation of After
RT
Hemorrhage
1
2
3
16/M
12/F
8/M
ALL
ALL
ALL
1800 WB
2400 WB
2400 WB
Seizures
Seizures
Sensorineural
hearing loss; L
facial
4
15/F
ALL
Headache
5
15/F
ALL
Unknown
WB
1800 WB
6
7
8
9
4/F
16/F
22/M
17/F
10
13/M
Medulloblastoma
3rd ventricle mass
ALL
Neurofibromatosis;
optic nerve
glioma
Medulloblastoma
11
17/F
12
8/F
3600
5350
2800
5400
WB/CSI
LF
WB
LF
Dysesthesia L
face, arm, leg
Seizures
Gait ataxia
R hemiparesis
Asymptomatic
Location
11 Frontal and temporal
8 Temporal
6 Internal auditory canal;
cerebellopontine
angle
9 Thalamus
10 Thalamus
1
13
8
10
Frontal
Vermis
Pons
Temporal
Follow-up
since
Hemorrhage, y
Outcome
1
6
6
No recurrent seizures
Seizures controlled
Resolution of facial
palsy (1 mo); later
recovery of
sensorineural
hearing loss (6 mo)
Unavailable Resolution of
symptoms
1.5
Resolution of
symptoms
5
Seizures controlled
2.5
Resolution of ataxia
2
Mild R hemiparesis
1
Asymptomatic from
hemorrhage
Asymptomatic
5 Parietal
1
Asymptomatic
Tectal glioma
5520 CSI/CD
PF
5400 LF
L hemiparesis
9 Pons
1
Medulloblastoma
5390
Coma
7 Pons
Major deficit, L
hemiparesis
Death secondary to
hemorrhage
3000 WB
2390 PF
5400 LF
Asymptomatic
5400 LF
Asymptomatic
2 Cerebellar hemisphere;
middle cerebellar
peduncle
7 Parietal
5400 LF;
1500
stereotactic
5824 LF
13
16/M
Pineal germinoma
14
22/M
15
14/F
Thalamic
astrocytoma
Cerebellar
astrocytoma
16
12/F
17
18
30/F
14/F
19
20
18/M
20/M
Malignant acoustic
neuroma
Thalamic glioma
Hypothalamic
oligodendroglioma
Frontal tumor
Lymphoma of
neck
Death
2
Asymptomatic
1
Asymptomatic
5 Cerebellar hemisphere
Nausea, vomiting,
brain stem
signs
Asymptomatic
10 Temporal
1.9
No new deficit
5000 LF
5400 LF
Asymptomatic
Asymptomatic
1
6000 LF
4750
2350 WB
2400 neck
Asymptomatic
L 3rd palsy and R
hemiparesis
19 Midbrain
4 Frontal
7 Frontal
9 Midbrain
.67
.67
4
4.5
Asymptomatic
Asymptomatic
Asymptomatic
Asymptomatic
Resolved R
hemiparesis;
persistent L 3rd
cranial nerve palsy
Note.—ALL indicates acute lymphoblastic leukemia; WB, whole brain; LF, local field; CSI, craniospinal irradiation; CD, coned down;
PF, posterior fossa; and RT, radiation therapy.
AJNR: 16, April 1995
and 11 had additional chemotherapy. The age
at which treatment (radiation and/or chemotherapy) was administered ranged from 1 to 15
years (mean, 6.9). The 7 children with leukemia/lymphoma were irradiated prophylactically. Nine patients (leukemia/lymphoma, 7;
medulloblastoma, 2) had whole-brain radiation
doses ranging from 1800 to 3600 centigray
(cGy) (median, 2400). Ten patients had localfield radiation doses ranging from 2400 to 6000
cGy (median, 5400), and 1 patient had craniospinal irradiation and coned-down radiation to
the posterior fossa at a dosage of 5520 cGy. Six
children with leukemia (patients 1 through 5
and patient 8) received some combination of
vincristine, prednisone, doxorubicin hydrochloride, methotrexate, asparaginase, cytarabine,
and mercaptopurine. Three children with
medulloblastoma (patients 6, 10, and 12) and 1
with a pineal germinoma (patient 13) were administered vincristine and cisplatin. One of the
patients with medulloblastoma (patient 12) also
received the MOPP regimen (mechlorethamine,
vincristine [Oncovin], prednisone, and procarbazine). The child with the mixed oligodendroglioma received procarbazine, lomustine, and
vincristine.
The onset of hemorrhage occurred along an
age range of 8 to 30 years (mean, 15.5). The
interval between treatment and hemorrhage
was 1 to 19 years (mean, 8.1). The radiation
dose to the area in which the hemorrhage occurred ranged from 1800 to 6000 cGy, as established by comparing the radiation planning
charts with CT and MR findings. The clinical
HEMORRHAGIC VASCULOPATHY
695
presentations for hemorrhage included brain
stem signs in 5 patients, seizures in 3 patients,
motor or sensory deficits in 2 patients, headache in 1 patient, and ataxia in 1 patient. Hemorrhage was demonstrated on routine surveillance or follow-up imaging in 8 patients. The
clinical follow-up was 0 to 6 years (mean, 2.25;
median, 1.5). Hemorrhages of varying ages
were identified in all 20 patients (Table; Figs
1– 4). Twenty-two lesions were seen, including
a single lesion in 18 patients and multiple lesions in two. Lesion sites included the cerebral
hemisphere (10), brain stem (5), thalamus (2),
cerebellar hemisphere (2), cerebellar peduncle
(1), cerebellar vermis (1), and cerebellopontine
angle (1). In the patients with primary brain
tumors, the majority of hemispheric lesions
arose remote from the original tumor location
(Figs 1–3), and not at a site of previous surgery.
The lesion diameters ranged from 0.3 to 3.2 cm,
with a mean diameter of 1.59 cm. In 10 of the
patients undergoing CT, high attenuation was
present in all lesions (Figs 2– 4). On T1weighted MR, 7 lesions were of mixed signal
intensity, 7 were isointense to white matter, 6
were hyperintense to white matter, and 1 was
hypointense to white matter (Figs 1, 3, 4). On
proton density– and T2-weighted MR, 13 lesions
had mixed signal intensities, 5 were hypointense, and 3 were hyperintense relative to white
matter (Figs 1, 3, 4). Of the 2 patients who
received intravenous contrast for CT, only slight
enhancement was seen in both. Of the 10 patients who received intravenous contrast for MR,
there was slight enhancement in 4. In 7 patients,
Fig 1. Fourteen-year-old girl (patient
18) with a history of hypothalamic mixed
oligodendroglioma and seeding diagnosed
at age 10 years, now stable 4 years after
radiation therapy.
A, Sagittal T1-weighted MR shows a hyperintense focus in the left frontal lobe
(arrow).
B, Axial T2-weighted MR shows a hyperintense focus in left frontal lobe consistent
with a small subacute hemorrhage (arrow).
696
POUSSAINT
AJNR: 16, April 1995
come. Neither the original diagnosis, radiation
dosage, chemotherapy, nor presence or absence of symptoms at the time of hemorrhage
correlate significantly with outcome. When
compared with patients with either cerebellar or
cerebral hemorrhage, those with brain stem
hemorrhage had a significantly worse prognosis, with new neurologic deficits in two and
coma evolving to death in the third (Fisher’s
Exact Test; P 5 .01).
Discussion
Fig 2. Eight-year-old girl (patient 12) with history of medulloblastoma diagnosed at age 17 months. After resection and
radiation therapy, the patient was stable until 7 years later, when
she presented with a seizure and obtundation. CT shows hemorrhage within the pons (asterisk) and extension into the third and
fourth ventricles.
the lesions evolved to a chronic, stable stage. In
2 patients, hemorrhage recurred as recognized
on follow-up imaging exams. One of these patients subsequently died and the other had surgical resection of the lesion. In 11 patients, no
follow-up imaging was conducted because they
had small subclinical lesions and have remained asymptomatic, or their minor symptoms quickly resolved and have not recurred.
With the exception of the 3 patients who received surgery, in no instance did the occurrence of hemorrhage alter the treatment program for any patient.
Histopathologic analysis was available in four
patients and showed no evidence of recurrent
nor second tumor. In one patient, there was
subacute hemorrhage with hemosiderin in the
adjacent tissues and radiation-induced vascular
change including large-vessel subintimal proliferation, vessel wall sclerosis, small-vessel proliferation, intramural fibrin, and mural necrosis.
In two patients, there was microvascular proliferation and intramural fibrin. A fourth patient
had acute hemorrhage and findings of gliosis,
hemosiderin-laden macrophages, fibrin, and
large dilated arborizing thin-walled endotheliallined channels (Fig 5).
We divided patients into groups according to
several variables to assess predictors of out-
The injurious effects of irradiation and chemotoxicity on the central nervous system are
well documented (6 –10). Radiation effects are
classified as acute injury (1 to 6 weeks after
irradiation), early delayed injury (3 weeks to
several months after irradiation), and late delayed injury (months to years after irradiation).
In acute injury, there is increased capillary permeability and vasodilation leading to vasogenic
edema. Early delayed injury includes vasogenic
edema and demyelination. The common late
delayed effects of irradiation include white matter necrosis, focal or diffuse demyelination, reactive astrocytosis, dystrophic mineralization,
gross atrophy, and radiation-induced vasculopathy. Vascular endothelial injury leads to disruption of the blood-brain barrier. Of these, focal or diffuse demyelination is most common in
children. The well-known ischemic vascular sequelae include proliferation of small blood vessels, hyalinization and fibrinoid necrosis of
blood vessel walls, and proliferation of the endothelial lining. As a result, there is narrowing
of the vascular lumen with ischemia and infarction. Other uncommon sequelae of central
nervous system irradiation include radiationinduced second tumors such as gliomas,
meningiomas, or sarcomas.
Hemorrhage is a rare, late delayed focal radiation effect that does not have an established
incidence. Of 11 cases reported in the literature
(1– 4), 6 included clinical and imaging data. In
our series, the majority (65%) of hemorrhages
occurred in the 13 patients who had received
radiation (8), or radiation with chemotherapy
(5), for primary brain tumors. Of the 6 patients
in the literature, 5 had primary brain tumors and
1 had a nasopharyngeal carcinoma. These were
reported in 4 children and 2 adults. In our series,
the onset of hemorrhage after treatment occurred with a mean of 8.1 years, which com-
AJNR: 16, April 1995
HEMORRHAGIC VASCULOPATHY
697
Fig 3. Sixteen-year-old girl (patient 7) with a history of an anterior third ventricular mass diagnosed at age 3 years without biopsy.
The patient was stable until 13 years after radiation therapy, when she presented with gait ataxia.
A, Axial CT shows an acute hemorrhage in the inferior vermis (arrow).
B, Sagittal T1-weighted MR shows an isointense lesion with peripheral T1 hyperintensity (arrow).
C, Axial T2-weighted MR shows the lesion (arrow) with a hypointense rim and surrounding high-intensity edema.
pares with a mean of 7 years in the cases reported in the literature. Radiation dosage for
cases in the literature for whole-brain or craniospinal irradiation ranged from 3600 to 5500
cGy, with local boost doses ranging from 600 to
1800 cGy. Only 1 patient of the 6 in the literature received chemotherapy, and was a patient
with a germinoma who received cyclophosphamide. No significant relationship was found
between intermediate outcome and radiation
dose, chemotherapeutic agent or dosage, age
at treatment, or interval between treatment and
hemorrhage in our series or in the literature,
although the numbers are small for the latter.
Of the 6 patients in the literature, only 1 was
asymptomatic, compared with eight in our series. The remaining 5 patients presented with
neurologic symptoms including dysphagia,
paraparesis, headache, and coma.
In our series, the majority of the hemorrhages
occurred in a supratentorial location. Of the six
patients previously reported, the majority of lesions occurred in the cerebral hemispheres (4),
one occurred in the spinal cord, and one occurred in the medulla. As in our series, these
lesions were hemorrhages of varying ages (ie,
acute, subacute, chronic), as diagnosed by MR,
and in no case was there associated tumor recurrence or second tumor. In this study, patho-
logic analysis in four patients concurred with the
findings in previous studies. Abnormal blood
vessels, vascular proliferation, and a telangiectatic histologic pattern were identified in five of
the six patients previously reported. In our series, as well as in the other reported cases, the
imaging appearances and pathologic findings
are often remarkably similar to those observed
with cavernous angiomas.
The pathogenesis of these hemorrhages as
related to radiation or chemotherapy is unclear.
Ball et al recently summarized three theories to
explain the pathophysiology of radiation injury
(8). One theory suggests that ionizing radiation
has an injurious effect on the endothelial cells,
resulting in injury to the endothelial lining, with
focal alterations in the fibrinolytic enzyme system leading to occlusion, thrombosis, and ischemia with infarction. A second theory hypothesizes direct injury to the parenchyma, and the
third theory postulates an immunologic mechanism with an allergic hypersensitivity response. The development of hemorrhages is
probably linked to disruption and alteration of
capillary vascular integrity by irradiation. Microscopically, large irregular capillary telangiectasias with proliferation of small blood vessels
have been described as a component of radia-
698
POUSSAINT
AJNR: 16, April 1995
Fig 4. Fifteen-year-old girl (patient 4) diagnosed with acute lymphoblastic leukemia at age 6 years and treated with radiation therapy
and chemotherapy. Nine years later she presented with headaches.
A, Axial CT shows an acute hemorrhage (arrow) in the left thalamus, and hydrocephalus.
B, Axial T2-weighted MR shows a hypointense lesion (arrows) with eccentric internal hyperintense foci and surrounding hyperintense
edema.
C, T2-weighted axial MR shows resolution of hydrocephalus and further evolution of hemorrhage, with a decrease in size of the lesion
(arrow), peripheral T2-weighted hypointensities, and areas of central hyperintensity.
tion injury (9). The latter may also provide the
source for hemorrhage.
The influence or contribution of chemotoxicity is uncertain in the 11 patients undergoing
additional chemotherapy in this series. Children
with intracranial hemorrhage related to chemotoxicity, including thrombocytopenia from myelosuppression, and cerebral or dural venous
thrombosis with hemorrhagic infarction from
asparaginase, were excluded. Otherwise, intracranial hemorrhage as a late or delayed event
Fig 5. Histologic findings in patients
with intracerebellar hemorrhage after radiation therapy.
A, Patient 7 (see also Figure 3). This
biopsy shows an increased number of vascular channels in the white matter. The
blood vessel walls are thickened and contain
smooth eosinophilic material concentrically
around the lumen (hematoxylin-eosin,
1453).
B, Patient 15. The resection shows dilated vascular channels, separated by thin
walls without intervening neuropil. The
channels are separated by red cells and collagenous stroma (hematoxylin-eosin, 363).
has not been linked specifically to chemotherapy toxicity nor to the effects of combined radiation and chemotherapy (10, 11).
In our series, brain stem hemorrhages were
associated with persistent neurologic sequelae
and death in one patient, whereas patients with
cerebral and cerebellar hemorrhages had better
outcomes. In the six patients reported in the
literature in whom the majority of the lesions
were cerebral, two deaths occurred in adults.
Three of the remaining four patients were chil-
AJNR: 16, April 1995
dren who were stable after surgery, and one
returned to prehemorrhage status (range, 5
months to 8 years).
In conclusion, delayed hemorrhage after radiation, or radiation combined with chemotherapy, is likely to be increasingly recognized as
more patients survive for longer periods. These
lesions should not be assumed to represent recurrent or second tumors. Even though a relatively benign outcome has been observed, except for brain stem hemorrhage, these patients
should be followed closely over longer periods
to establish a better understanding of the natural history and significance of this entity.
Acknowledgments
We thank Virginia Grove for manuscript preparation
and Donald Sucher for photography.
References
1. Allen JC, Miller DC, Budzilovich GN, Epstein FJ. Brain and spinal
cord hemorrhage in longterm survivors of malignant pediatric
brain tumors: a possible late effect of therapy. Neurology 1991;
41:148 –150
HEMORRHAGIC VASCULOPATHY
699
2. Chung E, Bodensteiner J, Hogg JP. Spontaneous intracerebral
hemorrhage: a very late delayed effect of radiation therapy. J
Child Neurol 1992;7:259 –263
3. Woo E, Chan YF, Lam K, Lok ASF, Yu Y-L, Huang CY. Apoplectic
intracerebral hemorrhage: an unusual complication of cerebral
radiation necrosis. Pathology 1987;19:95–98
4. Pendlebury WW, Anderson ML, Goldsby RE, Sullivan JK. Intracerebral hemorrhage as a complication of delayed radionecrosis.
J Neuropathol Exp Neurol 1991;50:370
5. Snedecor GW, Cochran WG. Statistical Methods. 7th ed. Ames:
Iowa State University Press, 1980:127
6. Russell DS, Rubinstein LJ. Pathology of Tumours of the Nervous
System. Baltimore: Williams and Wilkins, 1989:873– 875
7. Rowley HA, Dillon WP. Iatrogenic white matter diseases. In: Edwards MK, ed. White Matter Diseases. Philadelphia, Pa: Neuroimaging Clinics of North America, 1993:379 –393
8. Ball WS, Prenger EC, Ballard ET. Neurotoxicity of radio/chemotherapy in children: pathologic and MR evaluation. AJNR Am J
Neuroradiol 1992;13:761–776
9. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J
Neuroradiol 1991;12:45– 62
10. Balis F, Holcenberg J, Poplock D. General principles of chemotherapy. In: Pizzo P, Poplack D, eds. Principles and Practice of
Pediatric Oncology. 2nd ed. Philadelphia: JB Lippincott, 1993:
197–246
11. Schick R, Jolesz F, Macklis R, Barnes P. MR diagnosis of dural
venous sinus thrombosis complicating L-asparaginase therapy. J
Comput Med Imag Graphics. 1989:319 –327